Thep resence of antiphospholipid antibodies (APLA)i sa ssociated with an increasedr isko fr ecurrent thrombosis and pregnancyloss.APLA areable to activateendothelialcells (EC)and induce an increase in the expression of inflammatory marker proteins,such as leukocyteadhesion molecules, tissuefactor or themonocyte chemoattractantprotein-1(MCP-1). Our objectivewas to investigate theeffectofstatins on EC activation inducedbyAPLA in vitro.IgG was purifiedfromthe plasma of six patients withAPLA andf romh ealthyc ontrols.ECw erei ncubated with patient IgG or with control IgG,inthe presence or absence of 5μM of fluvastatin, and expression of theleukocyte adhesion molecules, VCAM-1 and E-selectin, analyzed by flow cytometry and by quantitativereverse transcriptase-PCR (QRTKeywords Antiphospholipid antibodies,endothelialcells,statins, tissue factor,celladhesion molecules PCR).The expression of tissuefactor and thechemokineMCP-1 was analyzed by QRT-PCR alone. IncubationofECwith patient IgG increasedthe expression of VCAM-1,E-selectin, tissue factor and MCP-1. Prior treatment of the cells with fluvastatin furtherincreasedthe expression of theseproteins.Thefluvastatin effect was reversedbyco-incubation with mevalonate or geranylgeranylpyrophosphateand mimicked by the geranylgeranyl transferase inhibitor GGTI-286. Our results show that in cultured human EC,statins increase theextent of inflammatory activation inducedbyAPLA.This effect appearstobemediated by an inhibitoryeffectofstatins on one or moregeranylgeranylated protein(s).
Introduction
The vascularendothelium represents adynamic barrierbetween blood and surrounding tissue and is amajor regulator of haemostasis, leukocyte migration and vasculartone. In response to activation by inflammatoryc ytokines, endothelial cells (EC) increase the expression of proteins involved in leukocyte recruitment, adhesion and transmigration leading to aproinflammatory phenotype.Among these proteins, adhesion molecules sucha s VCAM-1, ICAM-1 and E-selectin,o rc hemokines, such as monocyte chemoattractant protein-1 (MCP-1) playanimportant role (1, 2) . In addition, expression of tissue factor is increased in activatedEC (3) .
In patients, the presenceo fa ntiphospholipida ntibodies (APLA) is associated with an increased risk of thrombosis and recurrent fetal loss. The occurrence of APLA with clinicalmanifestationsc haracterizest he antiphospholipid syndrome (APS). Several studiesh aves hown that incubation of EC with APLA leads to an increased expression of leukocyte adhesion molecules and of tissue factor,a nd enhance monocyte adhesion in vitro (4) (5) (6) . Furthermore, in vivo,APLAincrease the adhesion of leukocytes to the endothelium in the cremaster muscle microcirculation modelinmice (7, 8) . In patients with APS,plasma levels of circulating markers of EC activation are increased (9, 10) . These observations suggest that in vivo and in vitro APLA induce EC activation, whichm ay contribute to their pathological effects.
Statins (3-hydroxy-3-methylglutaryl coenzyme Areductase inhibitors) are cholesterol-lowering drugsand arewidely used in the treatment of hyperlipidemia to prevent cardiovascularcom-plications. Theyinhibit the formation of mevalonate,aratelimiting intermediateinthe biosynthesis not onlyofcholesterol but also of farnesyl-and geranylgeranyl-pyrophosphate, whichprovide lipid anchorsthat arerequired forthe biologicalactivity of small GTPbindingproteins. More thanone hundredsmall GTP binding proteins have beeni dentified. Theya re classified into five families, includingthe Ras and Rho protein families, which playkey roles in the regulation of gene expression and of the organization of the cytoskeleton.The inhibition of the farnesylation or geranylgeranylation of small GTP binding proteins may underlie manyofthe pleiotropic effects of statins (11) .The antiinflammatorye ffect of statins hasb een reportedi ns everal studies, and maycontribute to their beneficial effects. However, the anti-inflammatoryeffectsofstatins on cytokine-mediated induction of leukocyte adhesion moleculee xpression in EC remain controversial. Several groups reported that statins inhibit adhesion moleculeexpression inducedbyproinflammarorycytokines in vitro (5, 12) . In contrast, others have shown thatstatins increased adhesion moleculee xpression inducedb yT NFα (13) (14) (15) (16) . Until now, fewstudiesfocusedonthe possible effect of statins on EC activation induced by APLA. In vitro,itwas shown thatfluvastatin, and to alesserextent simvastatin, reduced both the adhesion of U937 monocyte-likec ells to APLA-treated humanu mbilical vein endothelialc ells (HUVEC) and the expression of E-selectin and ICAM-1 (5).F urthermore,i na n in vivo study,f luvastatin treatment reduced thrombus size, the number of adherentl eukocytes and soluble ICAM-1 concentrations in micetreated with APLA (17) .
The aim of our study wastoinvestigatethe influenceofstatins on the synthesis and expression of several inflammation-relatedp roteinsb yA PLA-activatedE C. We showt hat, in EC treatedw ith IgG from patients with APLA, statins furtheri ncrease the expression of the leukocyte adhesion molecules VCAM-1 and E-selectin,ofthe monocyte chemoattractant protein MCP-1 and of tissue factor.T he statin-mediatedi ncrease wasprevented by the addition of mevalonate or GGPP and mimickedb yt he addition of the geranylgeranyl transferase inhibitor GGTI-286.
Material andmethods Reagents
Fluvastatin and the geranylgeranyl transferasei nhibitor-286 (GGTI-286) were obtainedf rom Calbiochem( SanD iego, CA, USA). Mevalonic acidl actonea nd geranylgeranyl-pyrophosphate (GGPP)w ere obtainedf rom Sigma (St. Louis, MO, USA). Mevalonic acidw as activatedb yt reatment with 0.1 M NaOH at 50°Cf or 2h ours; then the pH wasa djusted to 7.4 with HCl. Monoclonala nti-VCAM-1 (anti-CD106), and anti-E-selectin (anti-CD62E/CD62P) antibodies were purchased from Serotec (Oxford,U K). FITC-conjugatedg oat anti-mouse antibodies used as secondarya ntibodies for flowc ytometry analysis, wasf rom Cappel Organon Technika (Durham NC, USA).
Patients,blood samples and isolation of IgG
Six patientswith APLA, and suffering from thrombotic complications and/or pregnancymorbidity,were chosenamong agroup of patients evaluatedinapreviousstudy for the ability of their IgG to induce cellactivation in vitro (18) . Theclinical and serological characteristics of these patients are summarizedintable 1. IgGs were isolatedf rom the patient plasmaso nP rotein A CL-4B Sepharose (AmershamPharmacia BiotechAB, Uppsala, Sweden). Proteinlevelswere measured by the bicinchoninic acid protein assay( BCA Protein assay, Pierce, RockfordI L, USA). Endotoxin levels, measured by the Limulus Amebocyte Lysate EndochromeAssay(Charles RiverLaboratories, Charleston SC, USA), were found to be belowthe detection limit (0.25 EU/ml) for all IgG samples at the concentration used in the activation assays. The negative control antibodyc onsisted of IgG prepared from apool of ten healthydonors.
APLAassays
The titers of anticardiolipin IgG in the patient plasmas were determinedaspreviouslydescribed and higher than5GPL Units (19) . Levels of anti-β 2GP1 IgG in plasma were evaluatedb y ELISA (20) and were positive in allpatients. Lupus anticoagulant wase valuateda ccording to the InternationalS ociety of Thrombosis and Haemostasis criteria using aPTT-LA and Staclot LA (Stago, Anières, France) and dilute Russell'sv iper venom tests (Dade Behring, Marburg,G ermany). Lupusa nticoagulant waspresentinfour out of 6patients. All APLAassays were repeated at leastonce at an intervalofatleastsix weeks. The purified IgG fractionswere analyzed foranticardiolipin and anti-β 2GP1 activity and found to be positive.
Isolationand cultureofendothelialcells
Endothelial cells( HUVEC)w ere isolatedf rom umbilical cord veins and cultured as described previously (21, 22) . Cells were passaged by 0.05% trypsin-0.02%EDTA (Seromed Biochrom KG, Berlin, Germany) treatment at asplit ratio of 1:2, and used betweenp assages1t o4 .The cell culture medium wasR PMI 1640 supplemented with 10% fetal calf serum (FCS) (Invitrogen,Carlsbad, CA,USA), 90 μ g/ml heparin (Roche,Reinach, Switzerland), 15 μ g/ml EC growth supplement (Upstate Biotechnology, LakePlacidNY, USA), 10 mM HEPES,100 IU/ml penicillin and 100 μ g/ml streptomycin (Gibco BRL-Life Technologies, Rockville MD,USA). TheFCS wasdecomplemented by treatment for onehour at 56°C.
Stimulationofendothelialcells with APLAand treatment with fluvastatinand inhibitors
HUVEC were growni n2 4-well plates. After reaching confluence,the cells were incubatedincomplete medium overnight with5μ Mfluvastatin with or without mevalonate (400 μ M) or GGPP (15 μ M). Then, culturemedium wasr eplaced by RPMI 1640,20% FCS, 10mM Hepes, 100 UI/ml penicillin and 100 μ g/ ml streptomycin, containing, where appropriate,fluvastatin, mevalonate and GGPP. Cells were stimulatedw ith purifiedI gG-APLA (0.5 mg/ml). Fornegativecontrols cells were incubatedin the same conditions with medium aloneornormal human serum IgG (0.5 mg/ml). Twenty-four hoursafter stimulation with IgG-APLA or control IgG, cellsw ere isolatedf or flowc ytometry analysis or mRNAextraction. Similar experiments were performed with HUVECa fter prior incubation for 48 hours with GGTI-286( 10 μ M). Fresh GGTI-286 solutions were added after 24 hours.Thereafter, cells were treated with IgG-APLAo rc ontrol IgG for 24 hours and cells or mRNA isolatedfor further analysis.
Analysis of adhesionmoleculeexpressiononECb y flowcytometry
Cells were examinedfor surfaceantigen expression by flow cytometryaspreviouslydescribed (15) .The cells were washedin RPMI and incubatedfor 1hour at 4°C with mouse monoclonal antibody (anti-E-selectin or anti-VCAM-1) at 10 μ g/ml in PBS (Gibco,BRL-Life Technologies, U.K.), 5% FCS and 0.02%so-dium azide. Cells were washedi nP BS-FCS-sodium azide and incubatedf or 1h our at 4°C with polyclonalF ITC-conjugated goat anti-mousea ntibodies, dissolvedi nP BS/FCS/sodium azide. Cells were washedinPBS-sodiumazide, harvested with trypsin-EDTA and,a fter centrifugation at 800gf or 5m inutes, fixedin2.5% formaldehyde, 2% glucose,0.02% sodium azide in PBS. Propidium iodide (10 μ lof50 μ g/ml)w as added to each sample. Non-viable propidium iodide-positive cells were gated out. Cell fluorescence wasm easured on aB ecton Dickinson FACScan flow cytometer(SanJose CA, USA). Atotal of 10000 viable cells were analysed per experimental sample. Data were analysed using Cellquest software (Becton Dickinson).
RNAextraction andreverse transcription
TotalR NA wase xtractedf rom cells, and treated with DNaseI, using RNeasy  kits (QiagenG mbH,H ilden, Germany).T he RNAy ield and purity were assessed by absorbance measurements at 260and 280 nm. From each sample, 1 μ gofRNA was used as template for cDNA synthesis using the ImPromII TM Reverse transcription system(Promega, Madison WI, USA).
Quantitative real time reversetranscriptase PCR assay
Relative mRNAlevelsofVCAM-1, E-selectin, MCP-1,and tissue factor were quantifiedb yr eal-time PCR usingt he cDNA templates, with an AppliedBiosystems Prism 7000instrument and SYBR-green  PCR master mix reagent (AppliedB iosystems, Warrington, UK). Specificf orwarda nd reverse primers used were respectively: VCAM-1: CATGGAATTCGAACCCAAACA and GACCAA-GACGGTTGTAT CTCTGG; E-selectin:A TCATCCTGCAACTTCACCa nd ACACCTCAC-CAAACCCTTC; MCP-1: GTCACCTGCTGCTATAACTTCand TGCTGCTGGTGATTCTTCTA; tissue factor:C TACTGTTTCAGTGTTCAAGCAGTGA and CAGTGCAATATAGCAT TTGCAGTAGC. Glyceraldehyde-3-phosphate dehydrogenase, used as the control gene, wasa mplifieda nd quantified using as af orwardp rimer GGTGAAGGTCGGAGTCAACa nd reverse primer CCATGGGTGGAATCATAT TG.
Data were analyzed using the ∆ C T method and AppliedBiosystems Prism software, according to the manufacturers instructions and expressed as fold increase over control cells to which no IgG or other agents had beenadded.
Statisticalanalysis
The effect of fluvastatino nt he cell surfacee xpression of VCAM-1 and E-selectin and on mRNA synthesis of VCAM-1, E-selectin, tissue factor and MCP-1 wasassessedbythe paired student'st-test.The statisticalanalysis of the effect of mevalonatewas also performed by the paired student'st-test.
Results
Effect of fluvastatinonadhesionmolecules and tissue factor expressioninnon stimulated HUVEC Fluvastatin aloneh ad no effect on VCAM-1 or Es electin expression as measuredb yf lowc ytometrya nalysis. We made a timecourse on the effect of 5 μ Mfluvastatin on mRNAlevelsof inflammatorymarker proteins.The maximum effect wasobserved at 16 h: indeed5μ Mfluvastatin induces a1.6 to 3.6-fold increase in VCAM-1, Eselectin, MCP-1 and tissue factor mRNAs (Fig. 1) .The increase wasreversed by cotreatment with mevalonate (notshown). 
-test).Fluvastatin wasusedat5μ M, aconcentration that is not cytotoxic (5) .

Effect of fluvastatinonthe expressionofVCAM-1, E-selectin,MCP-1 and tissuefactor mRNA by IgG-APLA-activatedHUVEC
We furtheri nvestigated the effect of fluvastatin on IgG-APLA -treated HUVECbymeasuring the mRNAlevelsofvariousinflammation-related proteins. HUVEC were incubatedovernight with or without fluvastatinand then stimulated with IgG-APLA for 24h (from 4o ut of the 6I gG-APLA samples). TotalR NA samples were isolated, reverse transcribed and quantitative RT-PCR analysis performedf or VCAM-1, E-selectin, MCP-1 and tissue factor.Levelsofeach mRNAwere similar in non-treated HUVEC and in HUVECtreated with control IgG. As shownin Figure 3 , mRNA levels of VCAM-1, E-selectin, tissue factor and MCP-1 increased after incubation with IgG-APLAf rom pa- ConfluentHUVEC were pretreated overnight with5μ Mfluvastatin, with5μ Mfluvastatin plus 400 μ Mmevalonate, with5μ Mfluvastatin plus 15 μ MGGPPorwith10 μ MGGTI-286. IgG-APLA,isolatedfrom theplasma of patientswithAPLA (P1toP6, 500μ g/ml),was addedto themedium for24hours and VCAM-1 or E-selectin expression at the cell surface wasmeasured by flow cytometry. A: (VCAM-1) and 2B (E-selectin):Representativeflowcytometryprofile obtainedwithIgG-APLA from patient 1: Irepresents expression in control HUVEC;IIin HUVEC incubatedfor 24 hwithIgG-APLA (500μ g/ml);III-V in HUVEC pretreated for18h withfluvastatin (5μ M) (III), fluvastatin(5μM) and mevalonate(400μ M)(IV) or GGPP(15μ M)(V) and then for24hwithIgG-APLA (500μ g/ml);and VI in HUVECpretreated for48h withGGTI (10 μ M) and then for24hwithIgG-APLA (500μ g/ml).C-D: Flowcytometryanalysis of VCAM-1 (C)and E-selectin (D) expression obtained withHUVEC treated withIgG-APLA from the6patients: controlcells (whitebars),HUVEC incubated with IgG-APLA(500μ g/ml) from patients P1 to P6 (black bars),HUVEC preincubated for18h with5μ Mfluvastatin (diagonallystripedbars),5μ Mfluvastatin and 400 μ Mmevalonate(dotted bars) or 5 μ Mfluvastatin and 15 μM GGPP (graybars) and then withIgG-APLA (500μg/ml), or preincubated for48h with10 μ M GGTI-286 (horizontallystripedbars) and then withIgG-APLA (500μ g/ ml).VCAM-1and E-selectin expression assessedbyapaired student's t-test differs significantly between cells treated withAPLA alone and cells pretreated withfluvastatin priortoIgG-APLA stimulation(p<0.01 forVCAM-1and p<0.01 forE-selectin).The reversaleffect of mevalonatewas assessedbyapaired student'st-test: p<0.005 forVCAM-1ex-pression andp<0.001 forE-selectinexpression.
tients, comparedt ou ntreatedH UVEC.S imultaneous stimulation of HUVECw ith fluvastatina nd IgG-APLA further increased mRNA expression of the four molecules(respectively p<0.05 for VCAM-1, p<0.01 for E-selectin, p<0.005 for MCP-1 and p<0.025 for tissue factor,paired student'st-test, n=4).
The effectoffluvastatinonIgG-APLA-induced overexpressionofadhesionmolecules, tissuefactor and MCP-1are relatedtothe isoprenoidpathway
The addition of 400 μ Mmevalonate partiallyreversed the overexpression of VCAM-1 and E-selectin observedb yflowcytometryinfluvastatin-and IgG-APLA-treated HUVEC (Fig. 2) . This confirms that the effect of fluvastatinisdue to the inhibition of HMG-CoA reductase. The difference betweenm ean fluorescence valueso btained with the combination IgG-APLA and fluvastatin with or without mevalonate assessedbyapaired student'st-test had apvalue <0.005 forVCAM-1and p<0.001 for E-selectin (n=6).
In apreviousstudy,wehaveshown that the increasing effect of statins (simvastatin and fluvastatin) on adhesion molecule expression inducedb yTNFα wasc ompletelyr eversed by GGPP (15 μ M) whereas FPP hadonlyapartialeffect,evenwhen higher doses were used (15) . Basedonthis result,westudiedthe effect of GGPP on the fluvastatin-mediatedincrease in VCAM-1, E-selectin, MCP-1 and tissue factor expression inducedb yI gG-APLA. Fig2Aand Bshows the resultsobtained by flow cytometryanalysis with IgG-APLA from one of the patients. (Patient 1). These resultsshowthat 15 μ MGGPPreverses the effect of fluvastatin to as imilare xtent as mevalonate.T reatment of HUVECw ith GGTI-286i nducedas ignificant increase in Eselectin or VCAM-1expression inducedbyIgG-APLA. Similar resultsw ere obtainedf or the six IgG-APLA samples (Fig 2C  and D) .
We studiedt he effect of mevalonate,t he isoprenoid intermediate GGPP as well as GGTI-286 on the expression of VCAM-1, E-selectin, MCP-1 and tissue factor mRNAa fter stimulation of EC with IgG-APLA (Fig. 3) . The enhancing effect of fluvastatin on the mRNA levels wasrevertedbycoincubation with 400 μ Mmevalonate or 15 μ MGGPP. Similarprofileswere obtainedfor the four IgG-APLA -positive patient IgG samples tested. Coincubation with GGTI-286 had asimilareffect as fluvastatin on the IgG-APLA induced mRNAoverexpression of the fourmolecules tested.
Discussion
In this studyweshowthat APLA from patients increase the expression of leukocyte adhesion molecules, of MCP-1 and of tissue factor and thatfluvastatin furtherenhances this stimulatory effect. The effects observedfor APLA on protein expression in EC confirmthe resultsofpreviousstudies (4) (5) (6) 23) . Induction of an adhesive phenotype on endothelial cell is not attributable to contaminating endotoxins since purified IgG from healthyd onors do not induce adhesion molecule expression and Limulus assays on sample preparations were confirmed to be endotoxin negative.Wetherefore conclude that the effect of APLA on EC is antibody specific.
As the so-called pleiotropic "anti-inflammatory" activity of statins represent an attractive mechanism for their beneficial clinical effectsinaddition to their well known cholesterol lowering effects (11, (24) (25) (26) , we examinedwhetherfluvastatin modified the APLA-induced up-regulation of VCAM-1, E-selectin, tissue factor and MCP-1.W eobservedthat preincubation with fluvastatin led to an additional increase in each mRNA in response to IgG-APLAtreatment of HUVEC. Theeffectsoffluvastatin on the expression of VCAM-1 and E-selectin, induced by IgG-APLA, were comparable with our previous observations on the effect of simvastatin and fluvastatin on the expression of adhesion moleculesinducedbyTNFα or LPS (15) .
Several studieshavebeen conducted to evaluate the effect of statins on EC activation induced by inflammatorycytokines with conflicting results. Part of these studies reported that statins were able to decreaseadhesion molecule expression and macrophage adhesion on EC stimulated by TNFα or LPS (5, 12) .F urthermore,statins were reported to decreasethe expression of tissue factor on macrophages stimulatedwith LPS (27) . From this, an attractivemechanism for aprotective effect of statins hasbeen proposed,inw hich statins decrease the inflammatoryresponse of the endothelium resulting in alower leukocyte adhesion and a lowertissue factor expression both on the endothelium and the attached leukocytes. These effects would then leadt oal ower procoagulant activity in inflammatoryr egions.I ns upportf or this hypothesis, fluvastatin wasreported to reduce tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fedr abbit (28) . In contrast, several other studies rather observedt hat statins or geranylgeranyltransferase inhibitors rather potentiated the cytokine-mediated increase in adhesion molecules (13) (14) (15) (16) . Several reasons for these discrepancies were putf orwardw ithoutf indingad efinitive explanation: the use of different compounds of the statin family, the diverse agonistsemployedinactivating the cells or differences in the techniqueso fe valuating adhesion molecules expression (29) .O ne recent study reported resultst hat mayr econcile,a t leastinpart, the discrepancies (16) . In this studystatins did increaseadhesion molecule expression on TNF-treatedEC, butdecreased adhesion moleculeclustering and monocyte-likecelladhesion. It is known that adhesion molecule clustering and leukocyte adhesion are dependent on members of the Rho familyof GTP-binding proteins (30) , whichr equireg eranylgeranylation for expression of their activities. In this model the effect of statins or geranylgeranyltransferase inhibitors on leukocyte adhesion is due to their inhibition of these small GTP-binding proteins, rather than to an inhibition of adhesion molecule responses to inflammatorymediators.
The effect of statins on the inflammatorypropertiesofAPLA wasi nvestigated in twop reviouss tudies: in an in vitro experiment, Meroni (5) reported that simvastatin and fluvastatin decreased the EC expression of E-selectin and ICAM-1 in response to immunopurified APLA. In am icrocirculation modelo fe xposed cremaster muscle, mice receiving intraperitoneally APLA and treated withfluvastatin showedsmallerthrombi, areduced numbero fa dherent leukocytes and decreasedl evelso fc irculating solubleICAM-1compared with animals receiving APLA withoutfluvastatin (17) . These tworesults impliedabeneficial effect of statins on the in vivo and in vitro response to APLA. Our findings contradictt hese results. We observedt hat fluvastatin alone inducedasmall increase in VCAM-1, E-selectin, MCP-1 and tissue factor mRNA. However, this effect wasnot detectedat the cellsurfaceb yflowcytometry. Kiener et al (31) foundthat treatment of human monocytes with lipophilic statins alone stimulated the production of MCP-1, IL8, TNFα and IL1β and markedlys ensitized the cells to subsequent challenge with inflammmatoryagents. Thus one explanation could be that statins "pre-stimulate" the cells leading to an enhancedr esponset o agonists sucha sc ytokines or APLA. The enhanceda dhesion molecule response of statin pre-treatedc ells not necessarily translatesi nto an increased inflammatoryr esponse in vivo.I ndeed, Bernot et al. (16) observedt hat statins increased the adhesion molecule response of TNF-treatedEC, butthat leukocyte adhesion wasdecreased duetoaninhibition of Rho geranylgeranylation, whichb lockthe clustering of adhesion moleculesat the EC surface.
Theeffect of fluvastatin wasHMG-CoA-reductase dependent sinceitwas reversed by mevalonate.Inaddition, the effect of fluvastatin wasinhibited by the isoprenoid intermediateGGPP and mimickedb yt he geranylgeranyl-transferase inhibitor GGTI-286, whichsuggests that the observedeffect is due to an inhibition of protein geranylgeranylation.These resultsare similartoour previous findings that the enhancing effect of simvastatin or fluvastatin on TNF α -o rL PS-induced E-selectin expression wasr eversed by GGPPa nd mimicked by GGTI-286. This indicates that the inhibition of protein geranylgeranylation, butnot of cholesterol synthesis, is associated with the effect of these statins (15) .M ore than one hundreds mall GTP-binding proteins arek nown that require post-translational geranylgeranylation for their anchoring to the cellmembrane, whichisessential fort heir activity.O ur data suggest that one or more of these geranylgeranylated proteins exertanegative retrocontrol on EC activation induced by APLA, TNFα or LPS.
In conclusion,our resultsshowthat statins potentiate the activation of endothelialcells in response to APLA, leading to an increased expression of leukocyte adhesion molecules, of a monocyte chemoattractant chemokine and of tissue factor.I n combination with an increased expression of tissue factor by adherent activatedm onocytes, these changes alone would be expected to leadt oa ni ncreased tendencyf or localt hrombus formation. This implies that the well-known clinical benefits of statins are notdue to adecreaseinthe inflammatoryresponseof endothelialcells to cytokines or autoantibodies. In addition, our findings suggest that ageranylgeranylated proteinlimits the response of endothelialcells to APLA.
